Trial Profile
A Phase I, Open Label, Multi-Center Study of TAS-109 Given by Continuous Intravenous 7-day Infusion in Patients with Advanced or Metastatic Solid Tumors.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2009
Price :
$35
*
At a glance
- Drugs Radgocitabine (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
- 24 Nov 2009 New trial record